Patient specific treatment sequencing in ER plus advanced breast cancer

被引：0
|
作者：
Johnston, Stephen [1 ,2 ,3 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Breast Canc Med, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
[3] Inst Canc Res, London, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2020年 / 180卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：590 / 590
页数：1
相关论文
共 50 条
  • [1] ABCE4 study: estetrol for treatment of advanced ER plus breast cancer
    Verhoeven, C.
    Schmidt, M.
    Dutman, A.
    Bennink, H. C.
    BREAST, 2017, 32 : S69 - S70
  • [2] Estetrol for treatment of advanced ER+ breast cancer
    Verhoeven, Carole
    Schmidt, Marcus
    Hoenig, Arnd
    Duennebacke, Jan
    Dutman, Ellen
    Krijgh, Jan
    Bennink, Herjan Coelingh
    CANCER RESEARCH, 2018, 78 (04)
  • [3] Estetrol for treatment of advanced ER+ breast cancer
    Schmidt, M.
    Honig, A.
    Verhoeven, C.
    Almstedt, K.
    Battista, M.
    Lenhard, H. G.
    Krijgh, J.
    Bennink, H. Coelingh
    CANCER RESEARCH, 2019, 79 (04)
  • [4] Whole exome and transcriptome sequencing of resistant ER plus metastatic breast cancer
    Cohen, O.
    Kim, D.
    Oh, C.
    Waks, A.
    Oliver, N.
    Helvie, K.
    Marini, L.
    Rotem, A.
    Lloyd, M.
    Stover, D.
    Adalsteinsson, V.
    Freeman, S.
    Ha, G.
    Cibulskis, C.
    Anderka, K.
    Tamayo, P.
    Johannessen, C.
    Krop, I.
    Garraway, L.
    Winer, E.
    Lin, N.
    Wagle, N.
    CANCER RESEARCH, 2017, 77
  • [5] TMPRSS2 serin protease is a novel biomarker for ER plus breast cancer patient prognosis and survival and mediates resistance to anti-estrogen treatment in ER plus breast cancer
    Ozyurt, Rumeysa
    Kahraman, Nermin
    Dundar, Pinar Atalay
    Ozpolat, Bulent
    CANCER RESEARCH, 2023, 83 (07)
  • [6] Clinical utility trials for CTC and ctDNA in ER plus advanced breast cancer
    Bidard, Francois-Clement
    CANCER RESEARCH, 2019, 79 (13)
  • [7] Single-cell RNA sequencing defines regulatory networks in ER plus breast cancer organ-specific metastases
    Just, Nuria Padilla
    Finlay-Schultz, Jessica
    Gillen, Austin E.
    Cittelly, Diana M.
    Wellberg, Elizabeth A.
    Horwitz, Kathryn B.
    Kabos, Peter
    Sartorius, Carol A.
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Lasofoxifene as a potential treatment for ER plus metastatic breast cancer.
    Laine, Muriel
    Fanning, Sean William
    Greene, Marianne
    Chang, Ya-fang
    Phung, Linda
    Tan, Tina T.
    Hiipakka, Richard
    Komm, Barry
    Greene, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER plus Breast Cancer
    Zboril, Emily K.
    Grible, Jacqueline M.
    Boyd, David C.
    Hairr, Nicole S.
    Leftwich, Tess J.
    Esquivel, Madelyn F.
    Duong, Alex K.
    Turner, Scott A.
    Ferreira-Gonzalez, Andrea
    Olex, Amy L.
    Sartorius, Carol A.
    Dozmorov, Mikhail G.
    Harrell, J. Chuck
    CANCERS, 2023, 15 (12)
  • [10] Patient poverty burden influences the molecular biology of ER plus breast cancer
    DeWitt, Jerry T.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
12345